SLC22A12 and gout: Given the fact that 90% of the patients with hyperuricemia are urate under-excretors, URAT1 inhibitors, which lower sUA by inducing uricosuria, were believed to be a very promising class of uricosuric agents for the treatment of hyperuricemia and gout [18].